DYN · NASDAQ · STOCK
Dyne Therapeutics (DYN) Stock Analysis
$16.64
52W $13.72 – $27.31
55/100
$3.11B
-5.0
1.12
Is DYN Bullish or Bearish?
Mixed.
Innellis AI committee rates Dyne Therapeutics, Inc. (DYN) Watch with a composite score of 55/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.63 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.37 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.22 across 9 articles, 14d) — News
Bear Case
- ROE of only -64.3% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Bollinger bandwidth of 21.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 63%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -64.3% -- cheap may mean cheap for a reason
Growth Analyst
bearish
35
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock
− Bollinger bandwidth of 21.9% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
65
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.22 across 9 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.4 to 55.4.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
52.1
Neutral
MACD Histogram
0.308
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$15.88
Resistance
$20.01
Bollinger %B
0.52
Inside Bands
Price vs Moving Averages
EMA 9
$16.17
Above
EMA 21
$17.32
Below
EMA 50
$19.63
Below
EMA 200
$19.57
Below
Fundamental Analysis
Valuation
88
Growth
33
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-5.0×
P/B Ratio
3.92×
PEG Ratio
-0.35
Dividend Yield
0.00%
52W High
$27.31
52W Low
$13.72
Quality & Growth
ROE
-4590.1%
ROA
-3759.3%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
P/E ratio of -5.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -45.9%; Return on assets of -37.6%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 12.02 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-3.02); Most recent quarter missed estimates by 42.4%; EPS growth decelerating (+3.9% -> -47.9% QoQ); Analyst estimates rising over recent quarters
Get the Full DYN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →